Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 3Terminated 1Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Carcinoma, Non-Small-Cell Lung 137Parkinson Disease 4, Autosomal Dominant Lewy Body 125Melanoma 95Neoplasms 75Squamous Cell Carcinoma of Head and Neck 65Colorectal Neoplasms 42Triple Negative Breast Neoplasms 38Carcinoma, Renal Cell 37Lung Neoplasms 36Stomach Neoplasms 35Head and Neck Neoplasms 34Breast Neoplasms 34Urinary Bladder Neoplasms 32Neoplasm Metastasis 32Carcinoma, Hepatocellular 32Pancreatic Neoplasms 30Ovarian Neoplasms 29Carcinoma, Transitional Cell 25Endometrial Neoplasms 19Recurrence 16Sarcoma 15Esophageal Neoplasms 15Carcinoma 15Uterine Cervical Neoplasms 14Prostatic Neoplasms 14Small Cell Lung Carcinoma 13Lymphoma 13Fallopian Tube Neoplasms 13Carcinoma, Squamous Cell 13Lymphoma, Non-Hodgkin 12

Interventions

Cyclophosphamide 19romidepsin 15fludarabine phosphate 13Whole-Body Irradiation 13Peripheral Blood Stem Cell Transplantation 11Mycophenolic Acid 11Doxorubicin 11Vincristine 10Prednisone 10Cyclosporine 1010-propargyl-10-deazaaminopterin 10Gemcitabine 8Etoposide 8Alemtuzumab 8Bortezomib 6Dexamethasone 5Busulfan 5Brentuximab Vedotin 5mogamulizumab 4denileukin diftitox 4darinaparsin 4Vitamin B 12 4Nivolumab 4Lenalidomide 4Folic Acid 4Carboplatin 4carfilzomib 3belinostat 3Tacrolimus 3Rituximab 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Lymphoma, T-Cell, Peripheral × pembrolizumab × Clear all
NCT02362997 2026-05-18

Pembrolizumab After ASCT for Hodgkin Lymphoma, DLBCL and T-NHL

Dana-Farber Cancer Institute

Phase 2 Completed
82 enrolled 20 charts
Lymphoid

Hodgkin Disease, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Peripheral

Data powered by HemOnc (CC BY 4.0) Colophon âš¡